COVID-19: Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development

COVID-19：艾滋病疫苗研发的非人类灵长类核心病毒学实验室

• 批准号: 10252317
• 负责人: THOMAS DENNY
• 金额: $ 57.4万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-12-22 至 2020-12-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10252317
• 关键词: 2019-nCoV; AIDS Vaccines; Acquired Immunodeficiency Syndrome; Animals; Biological Assay; COVID-19; Contracts; Ensure; HIV/SIV vaccine; Immunologics; Immunology; Laboratories; Measurement; National Institute of Allergy and Infectious Disease; Performance; Research Personnel; Site; Standardization; Therapeutic; Vaccines; immunogenicity; nonhuman primate; pre-clinical; preclinical study; research and development; vaccine efficacy; vaccine evaluation; viral RNA; virology

The NIAID Division of AIDS has a requirement for the conduct of quantitative viral RNA measurements for assessment of HIV/SIV vaccine efficacy in preclinical studies with nonhuman primates. The NIAID provides immunological and virological support for nonhuman primate studies conducted at NIAID’s Simian Vaccine Evaluation Unit contract sites (SVEUs) and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development, previously called the NHP “Core Laboratories.” The objective of the Core Laboratories has been to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines. This project will support the performance of viral RNA assays in support of animal studies evaluating SARS CoV-2 vaccine and therapeutic products.

NIAID 艾滋病部门要求进行定量病毒 RNA 测量，以评估非人类灵长类动物临床前研究中的 HIV/SIV 疫苗功效。 NIAID 为非人灵长类动物研究提供免疫学和病毒学支持，这些研究在 NIAID 猿猴疫苗评估单位合同地点 (SVEU) 进行，并由艾滋病疫苗研究人员通过三个用于艾滋病疫苗研究和开发的非人灵长类动物免疫学和病毒学实验室（以前称为 NHP“核心实验室”）提供。核心实验室的目标是确保临床前 NHP 研究测定的标准化和可比性，并为评估候选 HIV 和 SIV 疫苗的免疫原性和功效提供共同基础。 该项目将支持病毒 RNA 检测的性能，以支持评估 SARS CoV-2 疫苗和治疗产品的动物研究。